Werewolf Therapeutics, Inc., an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, today announced the completion of its $72 million Series B financing. The proceeds from the Series B financing will advance Werewolf's lead INDUKINE™ product candidates, WTX-124 (interleukin-2, or IL-2) and WTX-330 (interleukin-12, or IL-12) through Phase 1 clinical proof-of-concept studies, and progress additional programs to Investigational New Drug application-readiness. INDUKINE™ molecules are a novel class of systemically delivered, conditionally activated proinflammatory immune modulators.
Who to call at Werewolf Therapeutics, and when
A new round usually means Werewolf Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Werewolf Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Werewolf Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Werewolf Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Werewolf Therapeutics
Location
200 Talcott Ave, 2nd Floor
Watertown, Massachusetts, United States
About
Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINETM molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Werewolf Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WatertownBiotechnologyHealthcareHealth CareTherapeutics